Travere Therapeutics, Inc. (NASDAQ: TVTX) has reported new exploratory biomarker findings from its Phase 3 PROTECT study showing that FILSPARI (sparsentan) produced greater reductions in four urinary markers associated with kidney inflammation and injury than irbesartan in adults with immunoglobulin A nephropathy. Presented at the American Society of Nephrology’s Kidney Week 2026 meeting in Denver on October 23, the analysis provides additional evidence of sparsentan’s biological activity, although it does not independently establish that the treatment modifies the underlying disease process.
The findings extend the evidence supporting FILSPARI beyond the proteinuria and kidney function measures that formed the basis of its clinical development and United States regulatory approval. The analysis involved 295 participants from the 404-patient PROTECT trial and assessed biomarkers associated with macrophage activation, B-cell activity, complement activation and inflammatory signalling over a treatment period extending to 110 weeks.
For Travere Therapeutics, the new results arrive as FILSPARI moves further into commercial use across two rare kidney diseases, following full United States Food and Drug Administration approval for IgA nephropathy in September 2024 and a separate focal segmental glomerulosclerosis indication in April 2026. The immediate significance is therefore not a new regulatory authorisation but a potentially more detailed understanding of how dual endothelin and angiotensin receptor antagonism affects kidney disease biology. Whether these exploratory findings ultimately support a broader disease-modification claim will depend on further mechanistic validation and their relationship with clinically meaningful outcomes.
What do the new FILSPARI biomarker results reveal about inflammation and injury in IgA nephropathy?
The PROTECT biomarker analysis examined four urinary measurements that reflect different biological pathways implicated in IgA nephropathy. These included soluble CD163, associated with macrophage activation; B-cell activating factor, or BAFF; the terminal complement complex C5b-9; and interleukin-6, an inflammatory signalling protein. Because these markers capture different aspects of inflammatory and immune activity, their combined assessment provides a broader biological perspective than measuring proteinuria alone.
At Week 110, Travere reported a 60.1% reduction from baseline in urinary soluble CD163 with FILSPARI, compared with a 26.0% reduction with irbesartan. BAFF declined by 64.4% in the sparsentan group and 45.2% in the comparator group, while C5b-9 fell by 50.2% and 7.3%, respectively. Interleukin-6 decreased by 45.4% among patients receiving FILSPARI, compared with an 8.7% increase among those receiving irbesartan.
The measurements were normalised to urinary creatinine and reported as least-squares mean percentage changes from baseline. The nominal p-values for the between-treatment comparisons were below 0.001 for soluble CD163 and interleukin-6, 0.02 for BAFF and 0.032 for C5b-9. Travere also reported reductions across the measured time points through Week 110, suggesting that the biomarker changes were sustained rather than confined to a single assessment.
The breadth of the changes is scientifically relevant because IgA nephropathy involves several interacting disease mechanisms. Abnormal immunoglobulin A-containing immune complexes can accumulate in kidney structures, triggering inflammatory responses, complement activation and progressive glomerular injury. Persistent damage can ultimately contribute to scarring, protein leakage and declining kidney function, creating a rationale for therapies that interrupt several downstream consequences of the disease.
However, the exploratory nature of the analysis limits the conclusions that can be drawn from the nominal statistical results. The biomarker findings were not the prespecified primary efficacy endpoint of PROTECT, and the reported p-values should not be interpreted as confirmatory evidence across four separately assessed biological pathways. Further work is needed to determine whether these changes are independent treatment effects, consequences of improved kidney function and reduced protein leakage, or a combination of mechanisms.
How do the new biomarker findings compare with the established Phase 3 PROTECT clinical results?
The underlying PROTECT study was a global, randomised, double-blind, active-controlled Phase 3 trial involving 404 adults with biopsy-confirmed IgA nephropathy. Participants had persistent proteinuria of at least 1 gram per day despite optimised renin-angiotensin system inhibitor treatment and an estimated glomerular filtration rate of at least 30 millilitres per minute per 1.73 square metres. They were assigned to receive sparsentan 400 milligrams daily or irbesartan 300 milligrams daily for up to 110 weeks.
The trial’s prespecified primary efficacy endpoint assessed proteinuria reduction at Week 36, while an important secondary endpoint measured the rate of kidney function decline through Week 110. In the previously published results, sparsentan produced a statistically significant reduction in proteinuria compared with irbesartan. The benefit was maintained over the two-year treatment period, providing evidence that the treatment’s effect on urinary protein excretion was durable within the study.
The final PROTECT analysis, published in The Lancet in 2023, reported a chronic estimated glomerular filtration rate decline of 2.7 millilitres per minute per 1.73 square metres annually with sparsentan, compared with 3.8 with irbesartan. The between-group difference was 1.1 millilitres per minute per 1.73 square metres annually, with a p-value of 0.037. The total estimated glomerular filtration rate slope analysis also numerically favoured sparsentan, although its p-value of 0.058 did not establish statistical significance under the conventional 0.05 threshold.
The newly presented biomarker analysis should be interpreted alongside these established clinical results rather than as an additional pivotal efficacy trial. Unlike an independent randomised study, it evaluates biological measurements collected within an existing trial population, with 295 of the original 404 participants included. Understanding the reasons for biomarker sample availability, missing measurements and potential differences between included and excluded participants is important when assessing the findings’ generalisability.
The value of the new analysis lies in connecting observed clinical outcomes with potential biological explanations. Proteinuria reduction and slower chronic kidney function decline provide the clinical context, while the urinary biomarker changes offer clues about pathways that may contribute to those outcomes. Establishing the direction and independence of those relationships would require additional research specifically designed to investigate the mechanisms involved.
Does the reduction in inflammatory biomarkers establish that FILSPARI modifies the underlying disease?
Disease modification is a particularly consequential concept in IgA nephropathy because the condition involves both disease-specific immune processes and kidney damage that develops over time. A treatment may slow the consequences of glomerular injury without directly correcting the immunological abnormalities responsible for initiating the disease. Distinguishing between these possibilities is essential when interpreting molecular and biomarker findings.
FILSPARI is a dual endothelin type A and angiotensin II type 1 receptor antagonist. Its pharmacological activity is intended to address pathways involved in vascular tone, glomerular pressure and kidney injury, combining two receptor-blocking actions within a single oral medicine. The new data suggest that this mechanism may also influence downstream inflammatory activity, although changes in urinary biomarkers do not establish direct effects on each immune pathway.
For example, reduced urinary complement-associated proteins may reflect changes in local inflammatory activation, improved glomerular integrity or altered urinary protein handling. Likewise, reductions in soluble CD163 and interleukin-6 may accompany lower kidney injury rather than demonstrate direct suppression of macrophage-driven or cytokine-mediated disease mechanisms. Distinguishing these explanations matters because the biological interpretation determines how far the findings can support a disease-modification hypothesis.
The results do not establish that sparsentan corrects the abnormal production of pathogenic immunoglobulin A or prevents the formation of nephritogenic immune complexes. They also do not demonstrate reversal of established kidney scarring or confirm that the observed biomarker changes independently predict a lower risk of kidney failure. Travere’s findings strengthen the rationale for further investigation of disease-related pathways, but the clinical interpretation must remain anchored to outcomes already demonstrated in PROTECT.
Longitudinal studies connecting biomarker changes with kidney function, proteinuria, treatment response and clinical outcomes could help establish whether specific measurements have prognostic or predictive value. Such evidence might eventually contribute to a more individualised understanding of treatment response, particularly if selected biomarkers reliably identify patients with persistent inflammatory activity despite improved conventional kidney measurements.
How does FILSPARI fit into the changing treatment landscape for progressive IgA nephropathy?
The treatment landscape for IgA nephropathy has become increasingly differentiated as therapies targeting kidney protection and disease-specific immune mechanisms have entered clinical practice or advanced through development. The Kidney Disease: Improving Global Outcomes 2025 clinical practice guideline reflects this distinction by addressing treatments that reduce nephron loss alongside approaches intended to influence pathogenic immunoglobulin A production and inflammatory injury. Within that framework, sparsentan is included as a suggested treatment for patients at risk of progressive kidney function decline.
Historically, management relied heavily on optimised blood pressure control and renin-angiotensin system inhibition, with immunosuppressive treatment reserved for selected patients. More recent therapeutic approaches include targeted-release budesonide, sodium-glucose cotransporter-2 inhibitors and medicines directed at immune or complement pathways. These developments create opportunities for more targeted treatment strategies, but they also increase the importance of understanding which mechanisms each intervention addresses and how combinations can be evaluated safely.
FILSPARI occupies a distinct position because it integrates endothelin and angiotensin receptor antagonism in a single non-immunosuppressive medicine. It replaces rather than supplements conventional angiotensin receptor blockade, meaning that its role in a treatment regimen must account for the restrictions associated with overlapping receptor-targeting therapies. The new biomarker findings add mechanistic context but do not establish that FILSPARI is superior to unrelated treatments evaluated in separate clinical trials.
The potential clinical significance is that nephrologists may eventually be able to interpret kidney function, proteinuria and molecular measurements together when assessing disease activity. However, no treatment-selection algorithm based on the four newly reported biomarkers has been established or authorised. Translating these research findings into clinical decision-making would require validated testing methods, defined thresholds and prospective evidence that biomarker-guided treatment improves outcomes.
What safety and treatment-access considerations remain important for FILSPARI?
FILSPARI’s commercial availability and favourable efficacy findings do not remove its established safety requirements. The medicine carries a United States boxed warning for hepatotoxicity and embryo-fetal toxicity, and access is controlled through a Risk Evaluation and Mitigation Strategy programme. Prescribers, patients and pharmacies must comply with the applicable programme requirements, creating additional operational responsibilities compared with medicines that do not require restricted distribution.
The current prescribing information calls for liver enzyme and bilirubin assessment before treatment and every three months during treatment. In clinical studies, elevations in alanine or aspartate aminotransferase levels of at least three times the upper limit of normal were observed in up to 3.5% of FILSPARI-treated patients. Pregnancy is contraindicated because of embryo-fetal toxicity risk, and the label also includes restrictions involving other angiotensin receptor blockers, endothelin receptor antagonists and aliskiren.
These requirements have practical implications for nephrology clinics, specialty pharmacies and patients receiving long-term treatment. Monitoring must remain consistent as prescribing expands, while treatment interruption, eligibility assessment and access procedures can influence treatment continuity. The biomarker announcement does not introduce a new safety analysis capable of changing these established prescribing obligations.
For payers and healthcare systems, the central question remains whether the treatment’s demonstrated effects on kidney function justify its total cost and associated monitoring requirements in eligible patient populations. The new molecular findings may strengthen the scientific narrative around the treatment, but reimbursement decisions will continue to place substantial weight on clinical outcomes, coverage criteria and the effectiveness of existing alternatives.
What do FILSPARI sales and Travere Therapeutics’ latest stock performance indicate about commercial expectations?
Travere’s second-quarter 2026 financial results showed that FILSPARI had already become a substantial commercial growth driver before the latest biomarker disclosure. United States net product sales of FILSPARI reached $141.1 million for the quarter ended June 30, representing growth of approximately 96% from the prior-year period. The company attributed demand to continued expansion in IgA nephropathy and the early commercial launch following the new focal segmental glomerulosclerosis approval.
The company also reported receiving 2,012 new patient start forms during the second quarter across the treatment’s commercial indications. This measure provides an indication of prescribing activity but should not be equated with confirmed treatment starts, sustained treatment or recognised revenue for every patient. Continued performance will depend on prescription conversion, treatment persistence, coverage access and the ability of commercial infrastructure to support the expanded approved population.
Travere shares closed at approximately $50.05 on October 23, 2026, down 4.5% for the trading session, although they remained slightly above their October 16 closing level. The shares were also below their September levels, indicating that investors were assessing the company against expectations extending beyond a single scientific presentation. The trading move should not be attributed solely to the Kidney Week data, particularly because the announcement did not involve a new approval or a change in the established pivotal trial results.
The longer-term commercial relevance of the biomarker findings will depend on whether they contribute to stronger physician confidence, further research or clinically validated approaches to monitoring kidney disease. Travere already possesses the central regulatory evidence supporting FILSPARI’s approved IgA nephropathy indication, so additional mechanistic information is more likely to support scientific positioning than trigger an immediate change in prescribing eligibility.
What further evidence could clarify FILSPARI’s potential disease-modifying effects?
The most useful follow-up research would connect individual biomarker trajectories with clinical outcomes over time and examine whether the measurements provide information beyond established indicators such as proteinuria and estimated glomerular filtration rate. Such analyses could determine whether patients experiencing the greatest reductions in inflammation-associated markers also experience better preservation of kidney function after adjustment for their baseline disease characteristics.
Investigations involving kidney tissue, complementary molecular profiling or independent patient cohorts could also help distinguish direct biological effects from changes secondary to improved glomerular function. Replication and mechanistic validation would be especially valuable before using the biomarker findings to support claims about effects on the initiating processes of IgA nephropathy.
The October 2026 PROTECT presentation provides a scientifically useful extension of an established clinical evidence package, rather than a new demonstration of clinical efficacy. Its longer-term value will depend on whether changes in soluble CD163, BAFF, C5b-9 and interleukin-6 can be connected reliably to the mechanisms and outcomes that matter in progressive kidney disease. For FILSPARI, the strongest demonstrated benefit remains its effects on proteinuria and kidney function, while the new biomarker findings offer a testable explanation for how those benefits may arise.
